

CURRICULUM VITAE

Paul Dennis Miller, MD, FACP

Updated November, 2018

Date of birth: November 9, 1943

Place of birth: Hagerstown, Maryland

Married: Linda Miller

Children: Kimberly, 1969; Jennifer, 1972; Kristin, 1974; Brittany, 1990; Devon, 1991

Citizenship: USA

Former position: Partner, Western Nephrology 1976-1992

Former position: Medical Director, solo private practice since 1992-2017
Colorado Center for Bone Research
3190 S. Wadsworth Blvd, #250
Lakewood, CO802
Panorama Orthopedics and Spine Center

Current Position: Medical Director
Colorado Center for Bone Research at Panorama Orthopedics and Spine Center
2017-Current

Education: Gettysburg College, Gettysburg, Pennsylvania, Biology, AB, 1965
The George Washington University (GWU) School of Medicine,
Washington, DC, Neuroanatomy, MS
GWU School of Medicine, MD, with honors, 1970

Postdoctoral training: University of Rochester School of Medicine (URSM),
Strong Memorial Hospital, Rochester, NY

- Medicine Internship, 1970-71
- Assistant Medical Resident, 1971-72
- Associate Medical Resident, 1972-73
- Chief Medical Resident, 1973-74

University of Colorado Medical Center (UCMC), Denver, CO

- Clinical Fellow in the Division of Renal Diseases, 1974-75
- Research Fellow in the Division of Renal Diseases, 1975-76

Academic appointments: UCMC, Denver, CO

- Instructor in Medicine, 1975-76
- Assistant Professor of Medicine, 1975-77
- Assistant Clinical Professor of Medicine, 1977-82
- Associate Clinical Professor of Medicine 1982-90
- Clinical Professor of Medicine, 1990-2005
- Distinguished Clinical Professor of Medicine, 2006-present

Licensure: Colorado, #18842

Board certified: American Board of Internal Medicine, 1973
American Board of Nephrology, 1976

Memberships: Alpha Omega Alpha
American Association of Clinical Endocrinologists
American College of Physicians, Fellow
American Federation for Clinical Research
American Medical Association
American Society for Bone and Mineral Research
American Society of Nephrology
Clear Creek Valley Medical Society
Colorado Medical Society
International Bone and Mineral Society
International Committee for Standards in Bone Densitometry
International Osteoporosis Foundation
International Society for Clinical Densitometry
Metabolic Bone Disease Society of Colorado
National Bone Health Alliance
National Osteoporosis Foundation
National Osteoporosis Society
Smith-Reed-Russell Medical Honor Society (GWU)
William Beaumont Research Society (GWU)

Student awards: Dodek Prize in Steroid Biochemistry (GWU), 1st in Biochemistry
GW Medical School
Perry Prize in Pathology (GWU), 1st in Pathology
Upjohn Achievement Award for Outstanding Academic Attainment
(GWU)
The William Beaumont Medical Research Society (GWU), First
prize, 1968
University of Texas National Research Forum, Third prize, 1968.

Postdoctoral awards: Honorary Doctor of Science, Gettysburg College, Gettysburg, PA,
1997
Distinguished Alumni Award, Gettysburg College, 1993
Distinguished Alumni Award, GWU, 2012
President's Award of the International Osteoporosis Foundation,
2014
Outstanding Teacher of the Year Award, Department of Medicine,
University of Colorado School of Medicine (UCSM), 1980-81
Outstanding Clinical Faculty Research Award, Department of
Medicine, UCSM, 1991
Outstanding Clinical Faculty Academic Publications Award, UCSM,
1995
Outstanding Volunteer Faculty, Denver Health and Hospitals, 1998
Outstanding Clinical Faculty Academic Publications Award,
University of Colorado Health Sciences Center, 2000
American College of Physicians Outstanding Internist of the Year
(Colorado), 1994
Career Achievement Award, Department of Medicine, University of
Colorado Health Sciences Center, 2005
Distinguished Clinical Professor of Medicine, Department of
Medicine, University of Colorado School of Medicine, 2008-
present
Fellow of The American Society for Bone and Mineral Research
2018

Professional activities: Program Chairman, Annual Meeting, The Colorado Chapter,
American College of Physicians, Colorado Springs, CO, January
1986
Founder and Program Chairman, Adult Clinical Working Group,

American Society for Bone and Mineral Research (ASBMR)

- Anaheim, CA, June 1986
- Indianapolis, IN, June 1987
- New Orleans, LA, June 1988

Founder: Metabolic Bone Disease Society of Colorado, 1984;
President, 1992-present

Board Member and Advisor, Osteoporosis Prevention Program,
Colorado Department of Health, 1991-2001

National Osteoporosis Foundation, Research Grant Committee of the
Scientific Advisory Board, 1993-present

ASBMR, Professional Practice Committee, 1995-2002; Publications
Committee 2011-present

National Osteoporosis Foundation, Osteoporosis: Clinical Updates
Newsletter, Editorial Board, 1995-present

Chairman, Steering Committee, Society for Clinical Densitometry,
1992-1996

Founding President, International Society for Clinical Densitometry,
1996-1999

Interspecialty Council, National Osteoporosis Foundation, 1999-
2004

Committee of Scientific Advisors, International Osteoporosis
Foundation, 2000-present

Board of Directors, International Osteoporosis Foundation 1996-
2011

ISCD representative to the NBHA Steering Committee to Enhance
Research, Surveillance & Evaluation in Osteoporosis, 2011-
present

ASBMR Executive Committee to help develop and oversee the
implementation of the Society's fundraising strategies for
individual annual and major gifts, corporate giving (educational
grants/sponsorship), planned giving/endowments, and foundation
support, 2014-present

- Journal editorial boards: *Journal of Women's Health*, 1998-present
Journal of Clinical Densitometry, 1998-2003
Calcified Tissue International, 2000-present
Journal of Clinical Densitometry, Editor-in-Chief, 2003-2011
Current Osteoporosis Reports, 2003-present (formerly *Osteoporosis: Index & Reviews*, 1995-2003)
Menopause Management, 2003-present
Osteoporosis International, 2005-present
Primer on the Metabolic Bone Disorders and Disorders of Mineral Metabolism (ASBMR), Associate Editor, 2008-present
Journal of Clinical Densitometry, Emeritus Editor-in-Chief, 2012-present
- Research grants awarded: Washington Heart Association Research Grant, 1965-66
National Kidney Foundation Research and Fellowship Grant, 1974-75
NIH Postdoctoral Fellowship, 1976-78
Rocky Mountain Kidney Foundation Research Grant, 1976-77
NIH Young Investigator Award, 1977
Principle investigator or co-investigator of >150 clinical trials and/or investigator-initiated trials

Publications/Articles

1. **Miller PD**, Telford IR, Haas GR. Effect of hyperbaric oxygen on cardiogenesis in the rat. *Biol Neonate*. 1971;17(1):44-52.
2. **Miller PD**, Waterhouse C, Owens R, Cohen E. The effect of potassium loading on sodium excretion and plasma renin activity in Addisonian man. *J Clin Invest*. 1975;56(2):346-353.
3. **Miller PD**, Schrier RW. When ions, not edema, dictate diuretics. *Drug Therapy*. 1976;6:141-153.
4. Cronin RE, Kaehny WD, **Miller PD**, Stables DP, Gabow PA, Ostroy PR, Schrier RW. Renal cell carcinoma: unusual systemic manifestations. *Medicine (Balt)*. 1976;55(4):291-311.
5. McDonald KM, **Miller PD**, Anderson RJ, Berl T, Schrier RW. Hormonal control of renal water excretion. *Kidney Int*. 1976;10(1):38-45.
6. **Miller PD**, Dubovsky SL, Schrier RW, McDonald KM, Arnaud C. Hypocalciuric effect of lithium in man. *Adv Exp Med Biol*. 1977;81:157-172.
7. Henrich WL, Cronin R, **Miller PD**, Anderson RJ. Hypotensive sequelae of diazoxide and hydralazine. *JAMA*. 1977;237(3):264-265.
8. **Miller PD**, Berns AS. Acute metabolic alkalosis perpetuating hypercarbia. A role for acetazolamide in chronic obstructive pulmonary disease. *JAMA*. 1977;238(22):2400-2401.
9. **Miller PD**, Heinig RE, Waterhouse C. Treatment of alcoholic acidosis: the role of dextrose and phosphorous. *Arch Intern Med*. 1978;138(1):67-72.

10. Schrier RW, Cronin RE, **Miller PD**, deTorrenté A, Burke TJ, Bulger R. Role of solute excretion in prevention of norepinephrine-induced acute renal failure. *Yale J Biol Med.* 1978;51(3):355-359.
11. Linas SL, **Miller PD**, McDonald KM, Stables DP, Katz F, Weil R, Schrier RW. Role of the renin-angiotensin system in post-transplantation hypertension in patients with multiple kidneys. *N Engl J Med.* 1978;298(26):1440-1444.
12. Cronin RE, de Torrente A, **Miller PD**, Bulger RE, Burke TJ, Schrier RW. Pathogenic mechanisms in early norepinephrine-induced acute renal failure: functional and histological correlates of protection. *Kidney Int.* 1978;14(2):115-125.
13. De Torrente A, **Miller PD**, Cronin RE, Paulsin PE, Erickson AL, Schrier RW. Effects of furosemide and acetylcholine in norepinephrine-induced acute renal failure. *Am J Physiol.* 1978;235(2):F131-F136.
14. Goodman M, Solomons CC, **Miller PD**. Distinction between the common symptoms of the phosphate-depletion syndrome and glucocorticoid-induced disease. *Am J Med.* 1978;65(5):868-872.
15. Anderson RJ, **Miller PD**. Mechanism of hypertension in nonazotemic patients with polycystic kidney disease. *Miner Electrolyte Metab.* 1979;2:137-141.
16. **Miller PD**, Krebs RA, Neal BJ, McIntyre DO. Hypomagnesemia. Suppression of secondary hyperparathyroidism in chronic renal failure. *JAMA.* 1979;241(7):722-723.
17. **Miller PD**, Dubovsky SL, McDonald KM, Katz FH, Robertson GL, Schrier RW. Central

- renal and adrenal effects of lithium in man. *Am J Med.* 1979;66(5):797-803.
18. **Miller PD**, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. *JAMA.* 1980;243(24):2513-2515.
 19. **Miller PD**, Krebs RA, Neal BJ, McIntyre DO. Polyuric prerenal failure. *Arch Intern Med.* 1980;140(7):907-909.
 20. Krebs RA, Fisher L, Neal BJ, McIntyre DO, **Miller PD**. Actinobacillus actinomycetemcomitans endocarditis with Henoch-Schonlein purpura. *Rocky Mtn Med J.* 1981;78:23-27.
 21. Szatalowicz VL, **Miller PD**, Lacher JW, Gordon JA, Schrier RW. Comparative effect of diuretics on renal water excretion in hyponatraemic oedematous disorders. *Clin Sci (Lond).* 1982;62(2):235-238.
 22. **Miller PD**, Krebs RA, Neal BJ, McIntyre DO. Hypodipsia in geriatric patients. *Am J Med.* 1982;73(3):354-356.
 23. **Miller PD**, Huffer W, Krebs RA, Neal BJ, McIntyre DO. Osteomalacia in adults: the value of bone histology in evaluating osteopenia. *Clin Res.* 1982;30:400.
 24. **Miller PD**. Prevention and treatment strategies for reducing incidence of osteoporotic fractures in older patients. *Ger Med Today.* 1988;7:23-29.
 25. **Miller PD**. Diagnosis and treatment of osteoporosis. *Int Med Specialist.* 1988;9:67-80.
 26. Watts NB, Harris ST, Genant HK, Wasnich RD, **Miller PD**, Jackson RD, Licata AA, Ross P,

- Woodson GC 3rd, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH 3rd. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. *N Engl J Med*. 1990;323(2):73-79.
27. **Miller PD**. Osteoporosis—recent developments in diagnosis and treatment. *Female Patient*. 1990;15:49-61.
28. Watts NB, Chesnut C, Heaney R, **Miller PD**. Osteoporosis—its prevention, diagnosis and treatment. *Med Times*. 1990;118:39-45.
29. **Miller PD**. Osteoporosis—new developments in prevention and treatment. *Physician Assist*. 1990;14:17-28.
30. Grimston SK, Sanborn CF, **Miller PD**, Huffer WE. Application of historical data for evaluation of osteopenia in female runners: the menstrual index. *Clin Sports Med*. 1990;2:108-118.
31. **Miller PD**, Neal BJ, McIntyre DO. The effect of cyclical phosphorus-etidronate therapy (ADFR) on axial bone mass in postmenopausal osteoporosis. *Osteoporos Int*. 1991;1(3):171-176.
32. **Miller PD**. The diagnosis and treatment of osteoporosis in primary care practice. *Modern Med*. January, 1992.
33. Ross PD, Genant HK, Davis JW, **Miller PD**, Wasnich RD. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. *Osteoporos Int*. 1993;3(3):120-126.

34. Conroy BP, Kraemer WJ, Maresh CM, Fleck SJ, Stone MH, Fry AC, **Miller PD**, Dalsky GP. Bone mineral density in elite junior Olympic weightlifters. *Med Sci Sports Exerc.* 1993;25(10):1103-1109.
35. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, **Miller PD**, Licata AA, Chesnut CH 3rd. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. *Am J Med.* 1993;95(6):557-567.
36. Ott SM, Woodson GC, Huffer WE, **Miller PD**, Watts NB. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. *J Clin Endocrinol Metab.* 1994;78(4):968-972.
37. Panigrahi K, Delmas PD, Singer F, Ryan W, Reiss O, Fisher R, **Miller PD**, Mizrahi I, Darte C, Kress BC. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. *Clin Chem.* 1994;40(5):822-828.
38. **Miller PD**. Bone densitometry and osteoporotic fracture risk. *Am Fam Physician.* 1994;50(5):922, 924, 929-930 passim.
39. **Miller PD**. Osteoporosis awareness in 1994. *Colo Med.* 1994;91(11):398.
40. **Miller PD**. Exercise and bones: A hard (or soft) choice. *Birch Scroll.* March 1995:24.
41. **Miller PD**. Cyclical etidronate for the treatment of postmenopausal osteoporosis. *Osteoporosis Japan.* 1995;3:22-28.

42. **Miller PD**, Harper KD. The World Health Organization criteria for the diagnosis of osteoporosis should be endorsed, pro and con. *Osteoporosis: Index Rev.* 1995;1:3,18,19.
43. **Miller PD**, Bonnicks SL, Rosen C. Guidelines for the clinical utilization of bone mass measurement in the adult population. Society for Clinical Densitometry. *Calcif Tissue Int.* 1995;57(4):251-252.
44. **Miller PD**. Critical drug appraisal: etidronate intermittent cyclic therapy for postmenopausal osteoporosis. *Br J Clin Pract.* 1996;50(1):23-31.
45. **Miller PD**, Bonnicks SL, Rosen CJ. Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. *Calcif Tissue Int.* 1996;58(4):207-214.
46. **Miller PD**, Bonnicks SL, Rosen CJ, Altman RD, Avioli LV, Dequeker J, Felsenberg D, Genant HK, Gennari C, Harper KD, Hodsmann AB, Kleerekoper M, Mautalen CA, McClung MR, Meunier PJ, Nelson DA, Peel NF, Raisz LG, Recker RR, Utian WH, Wasnich RD, Watts NB. Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry. *Semin Arthritis Rheum.* 1996;25(6):361-372.
47. **Miller PD**. The interpretation of bone mineral density: clues to misdiagnosis. *Osteoporosis: Index Rev.* 1996;2:8-9.
48. **Miller PD**, McClung M. Prediction of fracture risk. I: Bone density. *Am J Med Sci.* 1996;312(6):257-259.

49. Ettinger B, **Miller P**, McClung M. Use of bone densitometry results for decisions about therapy for osteoporosis. *Ann Intern Med.* 1996;125(7):623.
50. **Miller PD**. Parathyroid dysfunction in renal disease. *Curr Opin Endocrinol Diabetes.* 1996;3(6):529-531.
51. **Miller PD**. Expanding the list of etiologic factors for osteoporosis in men. *Endocr Pract.* 1997;3(4):261-263.
52. Epstein S, **Miller PD**. Bone mass measurements: the case for selected screening? *Trends Endocrinol Metab.* 1997;8(4):157-160.
53. Baran DT, Faulkner KG, Genant HK, **Miller PD**, Pacifici R. Diagnosis and management of osteoporosis: Guidelines for the utilization of bone densitometry. *Calcif Tissue Int.* 1997;61(6):433-440.
54. Osteoporosis Quality of Life Study Group. Measuring quality of life in women with osteoporosis. *Osteoporosis Int.* 1997;7(5):478-487. [Dr Miller was a member of the Study Group.]
55. **Miller PD**, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH 3rd. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. *Am J Med.* 1997;103(6):468-476. Erratum in: *Am J Med* 1998;104(6):608.
56. Hanson J for the International Committee for Standards in Bone Measurement. Letter to the Editor: Standardization of femur BMD. *J Bone Miner Res.* 1997;12(8):1316-1317. [Dr Miller

was a member of the Committee.]

57. Glüer C-C. Quantitative ultrasound techniques for the assessment of osteoporosis: expert agreement on current status. The International Quantitative Ultrasound Consensus Group. *J Bone Miner Res.* 1997;12:1280-1288. [*Dr Miller was a member of the Consensus Group.*]
58. **Miller PD.** Efficacy and safety of cyclical etidronate therapy in the long-term treatment of osteoporosis. *Rev Contemp Pharmacother.* 1998;9:255-260.
59. Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang R, McClung MR, Mallette LE, **Miller PD**, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. *J Bone Miner Res.* 1998;13(6):1032-1038.
60. **Miller PD**, Bonnick SL, Johnston CC, Kleerekoper M, Lindsay RL, Sherwood LM, Siris ES. The challenges of peripheral bone density testing: which patients need additional central density skeletal measurements? *J Clin Densitom.* 1998;1(3):211-217.
61. Siris E, **Miller P**, Barrett-Connor E, Abbott T, Sherwood L, Berger M. Design of NORA, the National Osteoporosis Risk Assessment Program: a longitudinal US registry of postmenopausal women. *Osteoporosis Int.* 1998;8 Suppl 1:S62-S69.
62. **Miller P**, Lukert B, Broy S, Civitelli R, Fleischmann R, Gagel R, Khosla K, Lucas M, Maricic M, Pacifici R, Recker R, Sarran HS, Short B, Short MJ. Management of postmenopausal osteoporosis for primary care. *Menopause.* 1998;5(2):123-131.
63. Cook DJ, Guyatt GH, Adachi JD, Epstein RS, Juniper EF, Austin PA, Clifton J, Rosen CJ,

- Kessenich CR, Stock JL, Overdorf J, **Miller PD**, Erickson AL, McClung MR, McClung BL, Griffith LE, Ioannidis G. Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group. *Osteoporosis Int.* 1999;10(3):207-213.
64. **Miller PD.** Management of osteoporosis. *Adv Intern Med.* 1999;44:175-207.
65. **Miller PD.** Management of osteoporosis. *Dis Mon.* 1999;45(2):21-54.
66. **Miller PD.** The use of risedronate in Paget's disease. *Bone.* 1999;24(5 Suppl):91S-92S.
67. **Miller PD**, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. *Am J Med.* 1999;106(5):513-520.
68. **Miller PD**, Zapalowski C, Kulak CA, Bilezikian JP. Bone densitometry: the best way to detect osteoporosis and to monitor therapy. *J Clin Endocrinol Metab.* 1999;84(6):1867-1871.
69. Bonnick SL, Faulkner KG, **Miller PD.** Qualifications for densitometry technologists: a position statement. *J Clin Densitom.* 1999;2(2):179-180.
70. **Miller PD**, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, Watts NB. Practical clinical application of biochemical markers of bone turnover. *J Clin Densitom.* 1999;2(3):323-342.
71. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, **Miller PD.** Effects of risedronate treatment

- on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. *JAMA*. 1999;282(14):1344-1352.
72. Faulkner KG, von Stetten E, **Miller P**. Discordance in patient classification using T-scores. *J Clin Densitom*. 1999;2(3):343-350.
73. Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, Nordin BEC, Barrett-Connor E, Black D, Bonjour J-P, Dawson-Hughes B, Delmas PD, Dequeker J, Eis SR, Gennari C, Johnell O, Johnston CC Jr, Lau EMC, Liberman UA, Lindsay R, Martin TJ, Masri B, Mautalen CA, Meunier PJ, **Miller PD**, Mithal A, Morii H, Papapoulos S, Woolf A, Yu W, Khaltsev N. Interim report and recommendations of the World Health Organization task-force for osteoporosis. *Osteoporosis Int*. 1999;10(4):259-264.
74. Watts NB, **Miller PD**. Changing perceptions in osteoporosis. Markers should be used as adjunct to bone densitometry. *BMJ*. 1999;319(7221):1371-1372.
75. **Miller PD**. Clinical application of bone density. *J Florida MA*. 2000;86:11-17.
76. Ettinger M, **Miller PD**, Notelovitz M. Bone mineral density testing: Who, when, how. *Patient Care*. 2000;35:62-81.
77. Wasnich RD, **Miller PD**. Antifracture efficacy of antiresorptive agents are related to changes in bone density. *J Clin Endocrinol Metab*. 2000;85(1):231-236.
78. Kanis JA, Glüer C-C, for the Committee of Scientific Advisors, International Osteoporosis Foundation. An update on the diagnosis and assessment of osteoporosis with densitometry.

- Osteoporosis Int.* 2000;11(3):192-202. [Dr Miller was a member of the Committee.]
79. **Miller PD.** Controversies in bone mineral density diagnostic classifications. *Calcif Tissue Int.* 2000;66(5):317-319.
80. Orwoll E, Ettinger M, Weiss S, **Miller P**, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. *N Engl J Med.* 2000; 343(9):604-610.
81. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J for the Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. *Osteoporosis Int.* 2000;11(suppl 6):S2-S17. [Dr Miller was a member of the Committee.]
82. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, **Miller P**, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. *Am J Med.* 2000;109(4):267-276.
83. Greenspan SL, Harris ST, Bone H, **Miller PD**, Orwoll ES, Watts NB, Rosen CJ. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. *Am Fam Physician.* 2000;61(9):2731-2736.
84. **Miller PD.** The treatment of osteoporosis. Antiresorptive therapy. *Clin Lab Med.* 2000;20(3):603-622.

85. **Miller PD**, Woodson G, Licata AA, Ettinger MP, Mako B, Smith ME, Wang L, Yates SJ, Melton ME, Palmisano JJ. Rechallenge of patients who discontinued alendronate therapy because of upper gastrointestinal symptoms. *Clin Ther.* 2000;22(12):1433-1442.
86. Sarno M, Sarno L, Baylink D, Drinkwater B, Farley S, Kleerekoper M, Lang R, Lappe J, Licata A, McClung M, **Miller P**, Natrass S, Recker R, Schwartz EN, Singer F, Tucci JR, Wolf S, Powell H, Tjersland G, Warnick GR. Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease. *Clin Chem Lab Med.* 2001;39(3):223-228.
87. Greenspan SL, Cheng S, **Miller PD**, Orwoll ES; QUS-2 PMA Trials Group. Clinical performance of a highly portable, scanning calcaneal ultrasonometer. *Osteoporosis Int.* 2001;12(5):391-398.
88. **Miller PD**. New possibilities for diagnosis and treatment of osteoporosis. *Int J Fertil Womens Med.* 2001;46(4):215-221.
89. Bonnick SL, Johnston CC Jr, Kleerekoper M, Lindsay R, **Miller P**, Sherwood L, Siris E. Importance of precision in bone density measurements. *J Clin Densitom.* 2001;4(2):105-110.
90. McClung MR, Geusens P, **Miller PD**, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. *N Engl J Med.* 2001;344(5):333-340.
91. **Miller PD**. Current controversies in bone densitometry. *Menopause Management.*

- 2001;May/June:22-32.
92. Adachi JD, Adami S, **Miller PD**, Olszynski WP, Kendler DL, Silverman SL, Licata AA, Li Z, Gomez-Panzani E. Tolerability of risedronate in postmenopausal women intolerant of alendronate. *Aging (Milano)*. 2001;13(5):347-354.
 93. **Miller PD**. Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis. *Osteoporos Int*. 2001;12(Suppl 3):S3-S10.
 94. Siris ES, **Miller PD**, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. *JAMA*. 2001;286(22):2815-2822.
 95. **Miller PD**. Is bone mineral density (BMD) measurement a sufficient and useful indicator of when to start osteoporosis treatment. *Medicographia*. 2002;24:343-344.
 96. Hochberg MC, Greenspan S, Wasnich RD, **Miller P**, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. *J Clin Endocrinol Metab*. 2002;87(4):1586-1592.
 97. Lenchik L, Leib ES, Hamdy RC, Binkley NC, **Miller PD**, Watts NB; International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee. Executive summary International Society for Clinical Densitometry position development conference Denver, Colorado July 20-22, 2001. *J Clin Densitom*. 2002;5(Suppl):S1-S3.

98. **Miller PD**, Njeh CF, Jankowski LG, Lenchik L; International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee. What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis? *J Clin Densitom.* 2002;5(Suppl):S39-S45.
99. Greenspan SL, Schneider DL, McClung MR, **Miller PD**, Schnitzer TJ, Bonin R, Smith ME, DeLucca P, Gormley GJ, Melton ME. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. *Ann Intern Med.* 2002;136(10):742-746.
100. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, **Miller PD**, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. *J Clin Endocrinol Metab.* 2002;87(10):4528-4535.
101. Khan AA, Brown J, Faulkner K, Kendler D, Lentle B, Leslie W, **Miller PD**, Nicholson L, Olszynski WP, Watts NB, Hanley D, Hodsman A, Josse R, Murray TM, Yuen K; International Society for Clinical Densitometry. Standards and guidelines for performing central dual X-ray densitometry from the Canadian panel of International Society for Clinical Densitometry. *J Clin Densitom.* 2002;5(4):435-445.
102. **Miller PD**, Bilezikian JP. Bone densitometry in asymptomatic hyperparathyroidism. *J Bone Miner Res.* 2002;17(Suppl 2):N98-N102.

103. Khan AA, Brown JP, Kendler DL, Leslie WD, Lentle BC, Lewiecki EM, **Miller PD**, Nicholson RL, Olszynski WP, Watts NB. The 2002 Canadian bone densitometry recommendations: take-home messages. *CMAJ*. 2002;167(10):1141-1145.
104. **Miller PD**, Siris ES, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Chen YT, Berger ML, Santora AC, Sherwood LM. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. *J Bone Miner Res*. 2002;17(12):2222-2230.
105. **Miller PD**. Defining strategies for improving the identification and management of osteoporosis in the primary care setting. *Int J Fertil Womens Med*. 2003;48(6):261-272.
106. **Miller PD**. Editorial: greater risk, greater benefit—true or false? *J Clin Endocrinol Metab*. 2003;88(2):538-541.
107. Kiebzak GM, **Miller PD**. Determinants of bone strength. *J Bone Miner Res*. 2003;18(2):383-384; author reply 385.
108. **Miller PD**. Bone mineral density—clinical use and application. *Endocrinol Metab Clin North Am*. 2003;32(1):159-179.
109. **Miller PD**. Bone mass measurements. *Clin Geriatr Med*. 2003;19(2):281-297.
110. **Miller P**. Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis. *South Med J*. 2003;96(5):478-485. Erratum in: *South Med J*. 2003;96(9):899.
111. Lenchik L, Leib ES, Hamby RC, Binkley NC, **Miller PD**, Watts NB. Position Development

- Conference. *South Med J*. 2003;96(7):724-725.
112. Siris ES, Chen YT, Weiss TW, Brenneman SK, **Miller PD**. The National Osteoporosis Foundation guidelines with peripheral BMD predict fractures in postmenopausal women. *Drug Benefit Trends*. 2003;15(7)36-42.
113. Barrett-Connor E, Wehren LE, Siris ES, **Miller PD**, Chen YT, Abbott TA 3rd, Berger ML, Santora AC, Sherwood LM. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. *Menopause*. 2003;10(5):412-419.
114. **Miller PD**. Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis. *Expert Opin Pharmacother*. 2003;4(12):2253-2258.
115. **Miller PD**, Bilezikian JP, Deal C, Harris ST, Ci RP. Clinical use of teriparatide in the real world: initial insights. *Endocr Pract*. 2004;10(2):139-148.
116. Olszynski WP, Davison KS, Adachi JD, Brown JP, Cummings SR, Hanley DA, Harris SP, Hodsman AB, Kendler D, McClung MR, **Miller PD**, Yuen CK. Osteoporosis in men: epidemiology, diagnosis, prevention. and treatment. *Clin Ther*. 2004;26(1):15-28.
117. **Miller PD**, Schnitzer T, Emkey R, Orwoll E, Rosen C, Ettinger M, Vandormael K, Daifotis A. Weekly oral alendronic acid in male osteoporosis. *Clin Drug Invest*. 2004;24(6):333-341.
118. **Miller PD**. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. *N Engl J Med*. 2004;350(2):190.

119. Yates J, Barrett-Connor E, Barlas S, Chen YT, **Miller PD**, Siris ES. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. *Obstet Gynecol.* 2004;103(3):440-446.
120. Khan AA, Bachrach L, Brown JP, Hanley DA, Josse RG, Kendler DL, Leib ES, Lentle BC, Leslie WD, Lewiecki EM, **Miller PD**, Nicholson RL, O'Brien C, Olszynski WP, Theriault MY, Watts NB; Canadian Panel of the International Society of Clinical Densitometry. Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. *J Clin Densitom.* 2004;7(1):51-64.
121. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, **Miller PD**, Wehen LE, Berger ML. Bone mineral density thresholds for pharmacological intervention to prevent fractures. *Arch Intern Med.* 2004;164(10):1108-1112.
122. **Miller PD**, Barlas S, Brenneman SK, Abbott TA, Chen YT, Barrett-Connor E, Siris ES. An approach to identifying osteopenic women at increased short-term risk of fracture. *Arch Intern Med.* 2004;164(10):1113-1120.
123. **Miller PD**. Pitfalls in bone mineral density measurements. *Curr Osteoporos Rep.* 2004;2(2):59-64.
124. Siris ES, Brenneman SK, **Miller PD**, Barrett-Connor E, Chen YT, Sherwood LM, Abbott TA. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and older: results from the National Osteoporosis Risk Assessment (NORA). *J Bone Miner Res.* 2004;19(8):1215-1220.

125. Hochberg MC, **Miller PD**, Wasnich RD, Ross PD, Greenspan S. Letter to the editor. *Bone*. 2004;35(5):1222-1224; author reply 1225-1226.
126. **Miller PD**. Combination therapy for osteoporosis: parathyroid hormone and bisphosphonates. *Curr Opin Orthop*. 2004;15(5):389-395.
127. **Miller PD**, Barlas S, Benneman SK, Abbott TA, Chen YT, Barrett-Connor E, Siris ES. An approach to identifying osteopenic women at increased short-term risk of fracture. *Obstet Gynecol Surv*. 2004;59(11):768.
128. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, **Miller PD**, Wehen LE, Berger ML. Bone mineral density thresholds for pharmacologic intervention to prevent fractures. *Obstet Gynecol Surv*. 2004; 59(11):769-771.
129. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, **Miller P**, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE; Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomizeddouble-blind study.*J Bone Miner Res*. 2005;20(1):141-151.
130. **Miller PD**. Diagnosis and treatment of osteoporosis or fragility fractures in patients with chronic kidney disease.*National Osteoporosis FoundationOsteoporosis Clinical Updates*. 2005;2:1-12.
131. **Miller PD**. Should low bone mass be treated? *Int J Fertil Womens Med*. 2005;50(2):83-87.
132. Barrett-Connor E, Siris ES, Wehren LE, **Miller PD**, Abbott TA, Berger ML, Santora AC,

- Sherwood LM. Osteoporosis and fracture risk in women of different ethnic groups. *J Bone Miner Res.* 2005;20(2):185-194.
133. Binkley N, Kiebzak GM, Lewiecki EM, Krueger D, Gangnon RE, **Miller PD**, Shepherd JA, Drezner MK. Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. *J Bone Miner Res.* 2005;20(2):195-201.
134. Cryer B, **Miller P**, Petruschke RA, Chen E, Geba GP, Papp AE. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. *Aliment Pharmacol Ther.* 2005;21(5):599-607.
135. **Miller PD**. Treatment of metabolic bone disease in patients with chronic renal disease: a perspective for rheumatologists. *Curr Rheumatol Rep.* 2005;7(1):53-60.
136. **Miller PD**. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. *Curr Osteoporos Rep.* 2005;3(1):5-12.
137. Chesnut CH, Ettinger MP, **Miller PD**, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. *Curr Med Res Opin.* 2005;21(3): 391-401.
138. **Miller PD**, Hochberg MC, Wehren LE, Ross PD, Wasnich RD. How useful are measures of BMD and bone turnover? *Curr Med Res Opin.* 2005;21(4):545-554.
139. **Miller PD**. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. *Clin Ther.* 2005;27(4):361-376.

140. Lewiecki EM, **Miller PD**, Leib ES, Bilezikian JP. Response to “The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry” by John A. Kanis et al. *Osteoporos Int*. 2005;16(5):579-580.
141. Lewiecki EM, **Miller PD**, Leib ES, Bilezikian JP. Response to “The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry,” by John A. Kanis et al. *J Clin Densitom*. 2005;8(2):143-144.
142. **Miller PD**, Shergy WJ, Body JJ, Chen P, Rohe ME, Krege JH. Long-term reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. *J Rheumatol*. 2005;32(8):1556-1562.
143. **Miller PD**, McClung MR, Macovei L, Stakkestad J, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. *J Bone Miner Res*. 2005;20(8):1315-1322.
144. Reid IR, **Miller P**, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakis K, Luchi M, Richardson P, Hosking D. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. *N Engl J Med*. 2005;353(9):898-908.
145. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, **Miller PD**, Olszynski WP, Orwoll E, Yuen CK. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested

- guidelines for its use. *Endocr Rev.* 2005;26(5):688-703.
146. McClung MR, San Martin J, **Miller PD**, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. *Arch Intern Med.* 2005;165(15):1762-1768. Erratum in: *Arch Intern Med.* 2005;165(18):2120.
147. **Miller PD**. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. *Curr Osteoporos Rep.* 2005;3(3):103-110.
148. Ettinger MP, Felsenberg D, Harris ST, Wasnich R, Skag A, Hiltbrunner V, Wilson K, Schimmer RC, **Miller PD**. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. *J Rheumatol.* 2005;32(10):1968-1974.
149. Felsenberg D, **Miller P**, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. *Bone.* 2005;37(5):651-654.
150. **Miller PD**, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. *J Bone Miner Res.* 2005;20(12):2105-2115.
151. Reid IR, **Miller PD**, Hosking D. Paget's disease and bisphosphonates. *New Engl J Med.* 2005;353(24):2617-2618.

152. **Miller PD**, Silverman SL, Gold DT, Taylor KA, Chen P, Wagman RB. Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study. *Osteoporos Int.* 2006;17(1):85-90.
153. Siris ES, Brenneman SK, Barrett-Connor E, **Miller PD**, Sajjan S, Berger ML, Chen YT. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). *Osteoporos Int.* 2006;17(4):565-574.
154. Leslie WD, Adler RA, El-Hajj Fuleihan G, Hodsmann AB, Kendler DL, McClung M, **Miller PD**, Watts NB; International Society for Clinical Densitometry. Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD official positions. *J Clin Densitom.* 2006;9(1):22-30.
155. Khan AA, Hanley DA, Bilezikian JP, Binkley N, Brown JP, Hodsmann AB, Josse RG, Kendler DL, Lewiecki EM, **Miller PD**, Olszynski WP, Petak SM, Syed ZA, Theriault D, Watts NB; Canadian Panel of the International Society for Clinical Densitometry. Standards for performing DXA in individuals with secondary causes of osteoporosis. *J Clin Densitom.* 2006;9(1):47-57.
156. Krege JH, **Miller PD**, Lenchik L, Misurski DA, Chen P. New or worsening lumbar spine vertebral fractures increase lumbar spine bone mineral density and falsely suggest improved skeletal status. *J Clin Densitom.* 2006;9(2):144-149.
157. Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, **Miller PD**, Kendler DL, Adami S,

- McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvoisin B, Recker RR, Delmas PD. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. *Osteoporos Int*. 2006;17(2):159-166.
158. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, **Miller PD**, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. *NEngl J Med*. 2006;354(8):821-831.
159. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, **Miller PD**. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. *Ann Rheum Dis*. 2006;65(5):654-661. Erratum in: *Ann Rheum Dis*. 2008;67(2):280.
160. **Miller PD**. Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. *Rev Endocr Metab Disord*. 2006;7(1-2):75-89.
161. Kaunitz AM, **Miller PD**, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. *Contraception*. 2006;74(2):90-99.
162. Lewiecki EM, Richmond B, **Miller PD**. Uses and misuses of quantitative ultrasonography in managing osteoporosis. *Cleve Clin J Med*. 2006;73(8):742-746, 749-752.
163. Chen P, **Miller PD**, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and

- vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. *J Bone Miner Res.* 2006;21(11):1785-1790.
164. Wagman RB, **Miller PD**. The use of teriparatide and PTH(1-84) for the treatment of osteoporosis. *Clinic Rev Bone Miner Metab.* 2006;4(4):277-290.
165. **Miller PD**. Is there a role for bisphosphonates in chronic kidney disease? *Semin Dial.* 2007;20(3):186-190.
166. Hosking D, Lyles K, Brown JP, Fraser WD, **Miller P**, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. *J Bone Miner Res.* 2007;22(1):142-148.
167. **Miller PD**, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. *Osteoporos Int.* 2007;18(1):59-68.
168. Kiebzak GM, Binkley N, Lewiecki EM, **Miller PD**. Diagnostic agreement at the total hip using different DXA systems and the NHANES III database. *J Clin Densitom.* 2007;10(2):132-137.
169. Carey JJ, Delaney MF, Love TE, Richmond BJ, Cromer BA, **Miller PD**, Manilla-McIntosh M, Lewis SA, Thomas CL, Licata AA. DXA-generated Z-scores and T- scores may differ substantially and significantly in young adults. *J Clin Densitom.* 2007;10(4):351-358.
170. **Miller PD**. Monitoring osteoporosis therapies. *Curr Osteoporos Rep.* 2007;5(1):38-43.

171. McClung M, Recker R, **Miller P**, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. *Bone*. 2007;41(1):122-128.
172. Chen P, **Miller PD**, Recker RR, Resch H, Rana A, Pavo I, Sipos AA. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. *J Bone Miner Res*. 2007;22(8):1173-1180.
173. Pazianas M, **Miller P**, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. *Clin Ther*. 2007;29(8):1548-1558.
174. Chen YT, **Miller PD**, Barrett-Connor E, Weiss TW, Sajjan SG, Siris ES. An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. *Osteoporos Int*. 2007;18(9):1287-1296.
175. **Miller PD**, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. *J Clin Endocrinol Metab*. 2007;92(9):3535-3541.
176. **Miller PD**. Intravenous bisphosphonate safety: the realities. *Bone*. 2007;41(5 suppl 1):S42-S43.
177. Weiss T, Siris ES, Barrett-Conner E, **Miller PD**, McHorney C. Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study. *Osteoporos Int*. 2007;18(11):1473-1480.

178. Lewiecki EM, **Miller PD**. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. *Expert Opin Drug Saf.* 2007;6(6):663-672.
179. Shane E, Civitelli R, Delmas PD, Drezner M, Eisman JA, Lindsay R, Lorenzo J, **Miller P**, Ralston S, Reid I, Siris E. Maintaining the trust of physicians and the public in the medical literature: report of a task force on scientific publishing of clinical trials. *J Bone Miner Res.* 2007;22(11):1661-1667.
180. Lewiecki EM, **Miller PD**, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA; AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study postmenopausal women with low BMD. *J Bone Miner Res.*2007;22(12):1832-1841.
181. **Miller PD**. (Guest Editor). The Osteoporosis Reports. From the 30th Annual Meeting of the American Society of Bone and Mineral Research. 2008;1(1):1-22.
182. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, **Miller P**, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF. The effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. *J Bone Miner Res.* 2008;23(1):6-16.
183. Lewiecki EM, Bilezikian JP, Cooper C, Hochberg MC, Luckey MM, Maricic M, **Miller PD**. Proceedings of the eighth annual Santa Fe Bone Symposium, August 3-4, 2007. *J Clin Densitom.* 2008;11(2):313-324.

184. **Miller PD**. Skeletal health and bone strength: DXA and beyond growth for the *Journal of Clinical Densitometry*. *J Clin Densitom*. 2008;11(1):1-5. Erratum in: *J Clin Densitom*. 2008;11(2):344.
185. Krieg MA, Barkman R, Gonelli S, Stewart A, Bauer DC, Del Rio Barquero L, Kaufman JJ, Lorenc R, **Miller PD**, Olszynski WP, Poiana C, Schott AM, Lewiecki EM, Hans D. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD official positions. *J Clin Densitom*. 2008;11(1):163-187.
186. Beck TJ, Lewiecki EM, **Miller PD**, Felsenberg D, Liu Y, Ding B, Libanati C. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. *J Clin Densitom*. 2008;11(3):351-359.
187. Watts NB, Lewiecki EM, **Miller PD**, Baim S. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organizations Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. *J Clin Densitom*. 2008;11(4):473-477.
188. Chen P, **Miller PD**, Binkley NC, Kendler DL, Wong M, Krohn K. Use of lowest single lumbar spine vertebra bone mineral density T-score and other T-score approaches for diagnosing osteoporosis and relationships with vertebral fracture status. *J Clin Densitom*. 2008;11(4):525-531.
189. **Miller PD**. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. *Curr Med Res Opin*. 2008;24(1):107-119.

190. **Miller PD**, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. *Curr Med Res Opin.* 2008;24(1):207-213.
191. Harris ST, Blumenthal WA, **Miller PD**. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. *Curr Med Res Opin.* 2008;24(1):237-245.
192. **Miller PD**, Ward P, Pfister T, Leigh C, Body JJ. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. *Clin Exp Rheumatol.* 2008;26(6):1125-1133.
193. **Miller PD**. Safety of parathyroid hormone for the treatment of osteoporosis. *Curr Osteoporos Rep.* 2008;6(1):12-16.
194. **Miller PD**, Chines AA, Christiansen C, Hoek HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. *J Bone Miner Res.* 2008;23(4):525-535. Erratum in: *J Bone Miner Res.* 2008;23(6):972.
195. Barrett-Connor E, Sajjan SG, Siris ES, **Miller PD**, Chen YT, Markson LE. Wrist fracture as a predictor of future fractures in younger versus older postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). *Osteoporos Int.* 2008;19(5):607-613.
196. Pazianas M, Blumentals WA, **Miller PD**. Lack of association between oral bisphosphonates

- and osteonecrosis using jaw surgery as a surrogate marker. *Osteoporos Int.* 2008;19(6):773-779.
197. **Miller PD**, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J; AMG Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized, blinded phase 2 clinical trial. *Bone.* 2008;43(2):222-229.
198. Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, **Miller PD**. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. *Kidney Int.* 2008;74(5):641-648.
199. **Miller PD**, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP; open-label study to determine how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of teriparatide investigators. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. *J Clin Endocrinol Metab.* 2008;93(10):3785-3793.
200. **Miller PD**. Anti-resorptives in the management of osteoporosis. *Best Pract Res Clin Endocrinol Metab.* 2008;22(5):849-868.
201. Fan B, Lewiecki EM, Sherman M, Lu Y, **Miller PD**, Genant HK, Shepherd JA. Improved precision with Hologic Apex software. *Osteoporos Int.* 2008;19(11):1597-1602.

202. **Miller PD.** The role of bone biopsy in patients with chronic renal failure. *Clin J Am Soc Nephrol.* 2008;3 Suppl 3:S140-S150.
203. Carey JJ, Delaney MF, Love TE, Cromer BA, **Miller PD**, Richmond BJ, Manilla-McIntosh M, Lewis SA, Thomas CL, Licata AA. Dual-energy X-ray absorptiometry diagnostic discordance between Z-scores and T- scores in young adults. *J Clin Densitom.* 2009;12(1):11-16.
204. Lewiecki EM, Baim S, Bilezikian JP, Eastell R, LeBoff MS, **Miller PD.** 2008 Santa Fe Bone Symposium: update on osteoporosis. *J Clin Densitom.* 2009;12(2):135-157.
205. Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, **Miller PD**, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adachi JD. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. *Osteoporos Int.* 2009;20(2):291-297.
206. Recker RR, Lewiecki EM, **Miller PD**, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. *Am J Med.* 2009;122(2 Suppl):S22-S32.
207. **Miller PD.** Diagnosis and treatment of osteoporosis in chronic renal disease. *Semin Nephrol.* 2009;29(2):144-155.
208. **Miller PD.** Denosumab: anti-RANKL antibody. *Curr Osteoporos Rep.* 2009;7(1):18-22.
209. McClung MR, Bolognese MA, Sedarati F, Recker RR, **Miller PD.**Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. *Bone.* 2009;44(3):418-422.

210. Baim SR, **Miller PD**. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. *J Bone Miner Res.* 2009;24(4):561-574.
211. Barrett-Conner E, Weiss TW, McHorney CA, **Miller PD**, Siris ES. Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). *Osteoporos Int.* 2009;20(5):715-722.
212. Lindsay R, **Miller P**, Pohl G, Glass EV, Chen P, Krege JH. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. *Osteoporos Int.* 2009;20(6):943-948.
213. Watts NB, **Miller PD**, Kohlmeier LA, Sebba A, Chen P, Wong M, Krohn K. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. *J Bone Miner Res.* 2009;24(6):1125-1131.
214. Watts NB, Lewiecki EM, Bonnick SL, Laster AJ, Binkley N, Blank RD, Geusens PP, **Miller PD**, Petak SM, Recker RR, Saag KG, Schousboe J, Siris ES, Bilezikian JP. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. *J Bone Miner Res.* 2009;24(10):1643-1646.
215. McClung MR, **Miller P**, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. *Obstet Gynecol.* 2009;114(5):999-1007.

216. **Miller PD**. Fragility fractures in chronic kidney disease: an opinion-based approach. *Cleve Clin J Med*. 2009;76(12):715-723.
217. **Miller PD**, Trippe K. *Clinical Updates: Osteoporosis and chronic kidney disease*. National Osteoporosis Foundation, 2010.
218. Lewiecki EM, Bilezikian JP, Laster AJ, **Miller PD**, Recker RR, Russell RG, Whyte MP. 2009 Santa Fe Bone Symposium. *J Clin Densitom*. 2010;13(1):1-9.
219. Hochberg MC, Silverman SL, Barr CE, **Miller PD**. The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. *J Clin Densitom*. 2010;13(2):181-189.
220. **Miller PD**. Fragility fractures in chronic kidney disease: a clarification of views. *Cleve Clin J Med*. 2010;77(2):75.
221. **Miller PD**. All bisphosphonates are (or may not be) the same: potential reasons for clinical differences. *J Womens Health (Larchmt)*. 2010;19(4):665-669.
222. Blank RD, Bilezikian JP, Bonnick SL, Laster AJ, Leib ES, Lewiecki EM, **Miller PD**, Watts NB, Binkley N. "Evidence-based" or "logic-based" medicine? *Osteoporos Int*. 2010;21(10):1681-1683.
223. Orwoll ES, **Miller PD**, Adachi JD, Brown J, Adler R, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrick P, Weinstein RS. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male

- osteoporosis: a randomized, multicenter, double-blind, active-controlled study. *J Bone Miner Res.* 2010;25(10):2239-2250.
224. Reid IR, **Miller PD**, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, MaasaluK, Bolognese MA, Woodson G, Bone H, Ding B, WagmanRB, San Martin J, Ominsky MS, DempsterDW; Denosumab Phase 3 Bone Histology Study Group. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. *J Bone Miner Res.* 2010;25(10):2256-2265.
225. **Miller PD**, Delmas PD, Huss H, Patel KM, Schimmer RC, Adami S, Recker RR. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. *Calcif Tissue Int.* 2010;87(4):305-313.
226. **Miller PD**, Derman RJ. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? *Osteoporos Int.* 2010;21(11):1793-1802.
227. Satterwhite J, Heathman M, **Miller PD**, Marín F, Glass EV, Dobnig H. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women. *Calcif Tissue Int.* 2010;87(6):485-492.
228. Lewiecki, EM, Bilezikian JP, Khosla S, Marcus R, McClung MR, **Miller PD**, Watts NB, Maricic M. Osteoporosis update from the 2010 Santa Fe Bone Symposium. *J Clin Densitom.* 2011;14(1):1-21.

229. Cummings SR, McClung M, Reginster JY, Cox D, Mitlak B, Stock J, Amewou-Atisso M, Powles T, **Miller P**, Zanchetta J, Christiansen C. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. *J Bone Miner Res.* 2011;26(2):397-404.
230. Lewiecki EM, Compston JE, **Miller PD**, Adachi JD, Adams JE, Leslie WD, Kanis JA; FRAX[®] Position Development Conference Members. FRAX[®] Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. *J Clin Densitom.* 2011;14(3):223-225.
231. Lewiecki EM, Compston JE, **Miller PD**, Adachi JD, Adams JE, Leslie WD, Kanis JA, Moayyeri A, Adler RA, Hans DB, Kendler DL, Diez-Perez A, Krieg MA, Masri BK, Lorenc RR, Bauer DC, Blake GM, Josse RG, Clark P, Kahn AA; FRAX[®] Position Development Members. Official positions for FRAX[®] bone mineral density and FRAX[®] simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX[®]. *J Clin Densitom.* 2011;14(3):226-236.
232. **Miller PD**. Vitamin D, calcium, and cardiovascular mortality: a perspective from a plenary lecture given at the annual meeting of the American Association of Clinical Endocrinologists. *Endocr Pract.* 2011;17(5):798-806.
233. **Miller PD**, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR. Effect of denosumab on bone mineral density and biochemical

- markers of bone turnover: six-year results of a phase 2 clinical trial. *J Clin Endocrinol Metab.* 2011;96(2):394-402.
234. Cosman F, Eriksen EF, Recknor C, **Miller PD**, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Buccui-Rechtweg C, Boonen S. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. *J Bone Miner Res.* 2011;26(3):503-511.
235. Bone HG, Bolognese MA, Yuen CK, Kendler DL, **Miller PD**, Yang YC, Grazette L, San Martin J, Gallagher JC. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. *J Clin Endocrinol Metab.* 2011;96(4):972-980.
236. **Miller PD**. The kidney and bisphosphonates. *Bone.* 2011;49(1):77-81.
237. Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, **Miller PD**. Effects of denosumab on fracture and bone mineral density by level of kidney function. *J Bone Miner Res.* 2011;26(8):1829-1835.
238. Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Montes J, **Miller PD**, Fraser WD, Cafoncelli S, Bucci-Rechtweg C, Hosking DJ. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. *J Bone Miner Res.* 2011;26(9):2261-2270.
239. **Miller PD**. Thanks and best wishes. *J Clin Densitom.* 2011;14(4):375-376.

240. **Miller PD.** A review of the safety and efficacy of denosumab in postmenopausal women with osteoporosis. *Ther Adv Musculoskelet Dis.* 2011;3(6):271-282.
241. **Miller PD,** Ragi-Eis S, Mautalen C, Ramirez F, Jonkanski I. Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease—the DIVINE study. *Bone.* 2011;49(6):1317-1322.
242. McClung MR, **Miller PD,** Brown JP, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough LK, Recker RR. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. *Osteoporosis Int.* 2012;23(1):267-276.
243. Lewiecki EM, Bilezikian JP, Jankowski LG, McCloskey EV, **Miller PD,** Morgan SL, Orwoll ES, Potts JT Jr. Proceedings of the 2011 Santa Fe Bone Symposium. *J Clin Densitom.* 2012;15(1):1-20.
244. Bilezikian JP, Zerbini C, Lewiecki E, Borges JL, **Miller PD,** Hans D, Camargos BM, McClung M. In Memoriam: Sergio Ragi-Eis, MD, CCD, CDT (April 8, 1962–February 22, 2012). *J Clin Densitom.* 2012;15(3):257-259.
245. Sajjan SG, Barrett-Connor E, McHorney CA, **Miller PD,** Sen SS, Siris E. Rib fracture as a predictor of future fractures in young and older postmenopausal women: National Osteoporosis Risk Assessment (NORA). *Osteoporos Int.* 2012;23(3):821-828.
246. Jamal SA, West SL, **Miller PD.** Fracture risk assessment in patients with chronic kidney disease. *OsteoporosInt.* 2012;23(4):1191-1198.

247. Lewiecki EM, Laster AJ, **Miller PD**, Bilezikian JP. More bone density testing is needed, not less. *J Bone Miner Res.* 2012;27(4):739-742.
248. Lewiecki EM, **Miller PD**, Bilezikian JP. Bone-density testing interval and transition to osteoporosis. *N Engl J Med.* 2012;366(16):1546-1547; author reply 1547-1548.
249. Boonen S, Ferrari S, **Miller PD**, Eriksen EF, Sambrook PN, Compston J, Reid IR, Vanderschueren D, Cosman F. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. *J Bone Miner Res.* 2012;27(5):963-974. Erratum in: *J Bone Miner Res.* 2012;27(11):2414-2415. *J Bone Miner Res.* 2012;27(11):2416.
250. **Miller PD**, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. *Osteoporos Int.* 2012;23(6):1747-1756.
251. Jamal SA, West SL, **Miller PD**. Bone and kidney disease: diagnostic and therapeutic implications. *Curr Rheumatol Rep.* 2012;14(3):217-223.
252. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, **Miller PD**, Neer RM, Recker RR, Shane E, Shoback D, Potts JT. Benefits and risks of bisphosphonate therapy for osteoporosis. *J Clin Endocrinol Metab.* 2012;97(7):2272-2282.
253. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, **Miller PD**, Woodson GC 3rd, Lindsay R, Binkley N,

- Wan X, Ruff VA, Janos B, Taylor KA. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. *J Clin Endocrinol Metab.* 2012;97(8):2799-2808.
254. **Miller PD.** Bone strength and surrogate markers: the first, second, and third fiddle. *J Bone Miner Res.* 2012;27(8):1623-1626.
255. **Miller PD,** Jamal SA, West SL. Bone mineral density in chronic kidney disease—use and misuse. *Clinic Rev Bone Miner Metab.* 2012;10:163.
256. Orwoll E, Teglbjærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, **Miller PD,** Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Siddhanti S, Grauer A, Hall JW, Boonen S. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. *J Clin Endocrinol Metab.* 2012;97(9):3161-3169.
257. **Miller PD.** Unrecognized and underappreciated secondary causes of osteoporosis. *Endocrinol Metab Clin North Am.* 2012;4(3):613-628.
258. Bauer D, Krege J, Lane N, Leary E, Libanati C, **Miller PD,** Myers G, Silverman S, Vesper HW, Lee D, Payette M, Randall S. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. *Osteoporos Int.* 2012;23(10):2425-2433.

259. **Miller PD**, Black DM, Hruska J, Boonen S. Renal effects of treatment with zoledronic acid: results from the HORIZON-PFT extension study. *Osteoporos Int*. 2012;23:S197-S198.
260. McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, **Miller PD**. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. *Osteoporos Int*. 2013;24(1):227-235.
261. Jamal SA . Secondary and tertiary hyperparathyroidism. *J Clin Densitom*. 2013;16(1):64-68.
262. Lewiecki EM, **Miller PD**. Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. *J Clin Densitom*. 2013;16(1):28-32.
263. Silverman S, **Miller PD**, Sebba A, Weitz M, Wan X, Alam J, Masica D, Taylor KA, Ruff VA, Krohn K. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. *Osteoporos Int*. 2013;24(8):2309-2317.
264. Lewiecki EM, Adler RA, Bilezikian JP, Bouxsein ML, Marcus R, McClung MR, **Miller PD**, Tanner SB, Randall S. Osteoporosis update from the 2012 Santa Fe Bone Symposium. *J Clin Densitom*. 2013;16(4):584-600.
265. Watts NB, Leslie WD, Foldes AJ, **Miller PD**. 2013 International Society for Clinical Densitometry Position Development Conference: task force on normative databases. *J Clin Densitom*. 2013;16(4):472-481.

266. McClung M, Harris ST, **Miller PD**, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. *Am J Med.* 2013;126(1):13-20.
267. **Miller PD**, Jamal SA, Evenepoel P, Eastell R, Boonen S. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. *J Bone Miner Res.* 2013;28(10):2049-2059.
268. Watts NB, Leslie WD, Foldes AJ, **Miller PD**. 2013 International Society for Clinical Densitometry Position Development Conference: task force on normative databases. *J Clin Densitom.* 2013;16(4):472-481.
269. **Miller PD**. Long-term extension trials to prove the efficacy and safety of bisphosphonates. *Clin Invest.* 2014;4(1):35-43.
270. **Miller PD**, Recker RR, Harris S, Silverman S, Felsenberg D, Reginster J, Day BM, Barr C, Masanauskaite D. Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. *Osteoporos Int.* 2014;25(1):349-357.
271. Lewiecki EM, Bilezikian JP, Bonewald L, Compston JE, Heaney RP, Kiel DP, **Miller PD**, Schousboe JT. Osteoporosis update: proceedings of the 2013 Santa Fe Bone Symposium. *J Clin Densitom.* 2014;17(3):330-343.
272. Lewiecki EM, **Miller PD**, Harris ST, Bauer DC, Davison KS, Dian L, Hanley DA, McClung MR, Yuen CK, Kendler DL. Understanding and communicating the benefits and risks of

- denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. *J Clin Densitom.* 2014;17(4):490-495.
273. Pazianas M, van der Geest S, **Miller PD**. Bisphosphonates and bone quality. *Bonekey Rep.* 2014;3:529.
274. Samelson EJ, **Miller PD**, Christiansen C, Daizadeh NS, Grazette L, Anthony MS, Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimomt N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. *J Bone Miner Res.* 2014;29(2):450-457.
275. Lubwama R, Nguyen A, Modi A, Chirovsky D, **Miller PD**. Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005-2008: is treatment with bisphosphonates an option? *Osteoporos Int.* 2014;25(12):2841.
276. Zangeneh F, Clarke BL, Hurley D, Watts NB, **Miller PD**. Chronic kidney disease–mineral and bone disorders (CKD-MBDs): what the endocrinologist needs to know. *Endocr Pract.* 2014;20(5):500-516.
277. Rothman MS, **Miller PD**, Lewiecki E, Bilezikian JP. Bone density testing: science, the media, and patient care. *Curr Osteoporos Rep.* 2014;12(2):227-229.
278. Kleerekoper M, Greenspan SL, Lewiecki EM, **Miller PD**, Kendler DL, Maricic M, Keaveny TM, Kopperdahl DL, Ruff VA, Wan X, Janos B, Krohn K. Assessing the effects of

- teriparatide treatment on bone mineral density, bone microarchitecture, and bone strength. *J Bone Joint Surg Am.* 2014;96(11):
279. **Miller PD.** Chronic kidney disease and osteoporosis: evaluation and management. *Bonekey Rep.* 2014;3:542.
280. **Miller PD.** Bone disease in CKD: a focus on osteoporosis diagnosis and management. *Am J Kidney Dis.* 2014;64(2):290-304.
281. Krege JH, Lane NE, Harris JM, **Miller PD.** PINP as a biological response marker during treatment for osteoporosis. *Osteoporos Int.* 2014;25(9):2159-2171.
282. Brown JP, Reid IR, Wagman RB, Kendler D, **Miller PD,** Jensen JE, Bolognese MA, Daizadeh N, Valter I, Zerbinski CA, Dempster DW. Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. *J Bone Miner Res.* 2014;29(9):2051-2056.
283. **Miller PD.** Chronic kidney disease and the skeleton. *Bone Res.* 2014 (2): 144-154.
284. Lewiecki EM, Bilezikian JP, Binkley N, Hans D, Krueger D, **Miller PD,** Oates M, Shane E. Update on osteoporosis from the 2014 Santa Fe Bone Symposium. *Endocr Res.* 2015;40(2):106-119.
285. **Miller PD,** McCarthy EF. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. *Semin Arthritis Rheum.* 2015;44(5):477-482.

286. Langdahl BL, Teglbjærg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, **Miller PD**, Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Mirza F, Siddhanti S, Orwoll E. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. *J Clin Endocrinol Metab.* 2015;100(4):1335-1342.
287. Manthripragada AD, O'Malley CD, Gruntmanis U, Hall JW, Wagman RB, **Miller PD**. Fracture incidence in a large cohort of men age 30 years and older with osteoporosis. *Osteoporos Int.* 2015;26(5):1619-1627.
288. Palcu P, Dion N, Ste-Marie LG, Goltzman D, Radziunas I, **Miller PD**, Jamal SA. Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report. *Am J Kidney Dis.* 2015;65(6):933-936.
289. **Miller PD**. It's hard to be a real doctor now. *Pharos Alpha Omega Alpha Honor Med Soc.* 2015;78(4):66-67.
290. Ferrari S, Adachi JD, Lippuner K, Zapalowski C, **Miller PD**, Reginster JY, Törring O, Kendler DL, Daizadeh NS, Wang A, O'Malley CD, Wagman RB, Libanati C, Lewiecki EM. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. *Osteoporos Int.* 2015;26(12):2763-2771.
291. **Miller PD**. Betsy McClung, 1942-2015. *J Bone Miner Res.* 2015;30:2139.

292. **Miller PD.** Clinical management of vertebral compression fractures. *J Clin Densitom.* 2016;19(1):97-101.
293. Lewiecki EM, Baron R, Bilezikian JP, Gagel RE, Leonard MB, Leslie WD, McClung MR, **Miller PD.** Proceedings of the 2015 Santa Fe Bone Symposium: clinical applications of scientific advances in osteoporosis and metabolic bone disease. *J Clin Densitom.* 2016;19(1):102-116.
294. **Miller PD.** Management of severe osteoporosis. *Expert Opin Pharmacother.* 2016;17(4):473-488.
295. Kendler DL, Bauer DC, Davison KS, Dian L, Hanley DA, Harris ST, McClung MR, **Miller PD,** Schousboe JT, Yuen CK, Lewiecki EM. Vertebral fractures: clinical importance and management. *Am J Med.* 2016;129(2):221-228.
296. **Miller PD.** Underdiagnosis and undertreatment of osteoporosis: the battle to be won. *J Clin Endocrinol Metab.* 2016;101(3):852-859.
297. Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, **Miller PD,** Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Janos B, Ruff VA. Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. *J Clin Endocrinol Metab.* 2016;101(4):1353-1363.
298. Rizzoli R, Benhamou CL, Halse J, **Miller PD,** Reid IR, Rodríguez Portales JA, DaSilva C, Kroon R, Verbruggen N, Leung AT, Gurner D. Continuous treatment with odanacatib for up

- to 8 years in postmenopausal women with low bone mineral density: a phase 2 study. *Osteoporos Int.* 2016;27(6):2099-2107.
299. Constantine GD, Kagan R, **Miller PD**. Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women. *Menopause.* 2016;23(6):638-644.
300. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao SD, **Miller PD**, Woodson GC 3rd, Lindsay R, Binkley N, Alam J, Ruff VA, Gallagher ER, Taylor KA. A longitudinal study of skeletal histomorphometry at 6 and 24 months across four bone envelopes in postmenopausal women with osteoporosis receiving teriparatide or zoledronic acid in the SHOTZ trial. *J Bone Miner Res.* 2016;31(7):1429-1439.
301. **Miller PD**, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. *J Clin Endocrinol Metab.* 2016;101(8):3163-3170.
302. **Miller PD**, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbin CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. *JAMA.* 2016;316(7):722-733.

303. **Miller PD**, Pannacciulli N, Wagman RB, Cummings SR. Response to the letter: Bone turnover as a potential determinant of bone mineral density increase following the transition from bisphosphonates to either denosumab or zoledronic acid. *J Clin Endocrinol Metab.* 2016;10(9):L91-L92.
304. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, **Miller PD**, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016—executive summary. *Endocrin Pract.* 2016;22(9):1111-1118.
305. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, **Miller PD**, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016. *Endocrin Pract.* 2016;22(Suppl 4):1-42.
306. Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, **Miller PD**, Rao DS, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Janos B, Ruff VA. Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study. *J Clin Endocrinol Metab.* 2016;101(4):1353-1363.
307. Cosman F, **Miller PD**, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D. Eighteen months of treatment with subcutaneous

- abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVE extend trial. *Mayo Clin Proc.* 2017;92(2):200-210.
308. McClung MR, Wagman RB, **Miller PD**, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. *Osteoporos Int.* 2017 Jan 31. doi: 10.1007/s00198-017-3919-1. [Epub ahead of print]
309. Watts NB, Aggers D, McCarthy EF, Savage T, Martinez S, Patterson R, Carrithers E, **Miller PD**. Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. *J Bone Miner Res.* 2017 Feb 7. doi: 10.1002/jbmr.3081. [Epub ahead of print]
310. Hanley DA, McClung MR, Davison KS, Dian , Harris MD ST, **Miller PD**, Lewiecki EM, Kendler DL; Writing Group for the Western Osteoporosis Alliance. Evaluating the balance of benefits and risks of long term osteoporosis therapies. *AJ Med* 2017; 130: 862-868. Review.
311. **Miller PD**. The history of dual energy x-ray absorptiometry. *BONE* 2017; 104: 4-6.
312. Klidas P, Aggers D, Carrithers E, Savage T, Martinez S, **Miller PD**. Asfotase alfa therapy heals recalcitrant bilateral pathologic femoral fractures in a patient with Hypophosphatasia after 1 year of treatment, that were previously non-healing up to 9 years. *J Bone Miner Res* 2017 (in press).
313. Rothman MS, Lewiecki EM, **Miller PD**. Bone Density Testing is the Best Way to Monitor Osteoporosis Treatment *Am J Med.* 2017 ; 130 (10): 1134-1134.

314. Watts NB, Aggers D, McCarthy EF, Savage T, Martinez S, Patterson R, Carrithers E, **Miller PD**. Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates. *J Bone Miner Res*. 2017; 32(5):1027-1033.
315. Lewiecki EM, Bilezikian JP, Bukata SV, Camacho P, Clarke BL, McClung MR, Miller PD, Shepherd. Santa Fe Bone Symposium. *J Clin Densitom*. 2017; 20(2):134-152.
316. Mclung M, **Miller PD**, Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide,
317. **Miller PD**, The efficacy and safety of denosumab versus continuing bisphosphonate therapy in postmenopausal women previously treated with oral bisphosphonates 2017
318. Rao Sudhaker D, Bilezikian JP, Watts, NB, **Miller PD**, McClung MR, Nelson D. Michael Keleekoper (August 18, 1944 to May 10, 2018): In Relentless Pursuit of a Better Way. (In Memorium) *JBMR* 2018; 1-3
319. Bone HG, Cosman F, **Miller PD**, Williams GC, Hattersley G, Hu Ming-yi, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG. ACTIVE Extend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. *J Clin Endo Metab* 2018; 103(8); 2949-2957.
320. **Miller PD**, Hattersley G, Lau E, Fitzpatrick LA, Harris AG, Williams GC, Hu M.Y., Black DM, Riis BJ, Russo L, Christiansen C. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide : results from the ACTIVE Phase 3 trial. *BONE*, 2018.

321. Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, **Miller PD**, Miyauchi A, Maddox J, Chen L, Horlait S. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of Romosozumab in men with osteoporosis. *JCEM* 2018; 103(9): 3183-3193.
322. **Miller PD**. Protecting academic thought and patient humanism in private practice. *The Pharos of Alpha Omega Alpha Honor Medical Society*. 2018; 81(3): 60-61.
323. **Miller PD**, Bilezikian JP, Lewiecki EM, Watts NB, Carey JJ. Re: A history of pivotal advances in clinical research into bone and mineral diseases. *JBMR* 2108; 33(10): 1900-1901).
324. **Miller PD**, Hattersley G, Lau E, Fitzpatrick LA, Harris AG, Williams GC, Hu MY, Riis BJ, Russo L, Christiansen C. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial. *Bone*. 2018 Oct 22;120:137-140. doi: 10.1016/j.bone.2018.10.015. [Epub ahead of print]
325. Lewiecki EM, Bilezikian JP, Giangregorio L, Greenspan SL, Khosla S, Kostenuik P, Krohn K, McClung MR, **Miller PD**, Pacifici R. the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis. *J Clin Densitom*. 2018 Sep 22. pii: S1094-6950(18)30200-2. doi: 10.1016/j.jocd.2018.09.010. [Epub ahead of print] Review.

326. McClung MR, Harvey NC, Fitzpatrick LA, **Miller PD**, Hattersley G, Wang Y, Cosman F. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. *Menopause*. 2018 Jul;25(7):767-771.
327. **Miller PD**. Ann Intern Med. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. 2017 19;167(12):903-904.

Textbooks and reports

1. Schrier RW, **Miller PD**. Water metabolism in diabetes insipidus and the syndrome of inappropriate antidiuretic hormone secretion. In: Kurtzman N, Martinez-Maldonado M, eds. *Renal Pathophysiology*. Taylor-Brown Publishers; 1976.
2. Schrier RW, **Miller PD**, Lacher JW. Diuretics and hyponatremia. *International Symposium on Diuretics*. Switzerland: Bockringer Mannheim; 1977:183-192.
3. Linas SL, Anderson RJ, **Miller PD**, Schrier RW. Rational use of diuretics in cirrhosis. In: Epstein M, ed. *The Kidney in Liver Disease*. New York, NY: Elsevier; 1978:313-331.
4. **Miller PD**. Osteoporosis and other metabolic bone diseases. In: Schrier RW, ed. *Geriatric Medicine: The Care of the Elderly Patient*. 2nd ed. Philadelphia, PA: WB Saunders Co; 1990:324-340.
5. **Miller PD**. Clinical interpretation and utility of bone densitometry. *Osteoporosis in Clinical Medicine*. In: Rosen CJ, ed. Totowa, NJ: Humana Press, Inc; 1996:113-119.

6. **Miller PD.** Bone mass in renal disease.*Osteoporosis in Clinical Medicine*.In: Rosen CJ, ed. Totowa, NJ: Humana Press, Inc; 1996:171-174.
7. **Miller PD.** Diagnostic prediction of increased risk of hip fracture:a clinician's perspective.In: Ringe J, ed. *Hip Fractures*. Stuttgart, Germany: Georg Thieme Verlag; 1996:53-62.
8. **Miller PD.** Osteoporosis in the elderly.In: Jahnigen D, Schrier RW, eds.*Geriatric Medicine*.2nd ed. Cambridge, MA: Blackwell Science, Co; 1996:534-557.
9. **Miller PD, Harris ST.**Clinical application of bone densitometry. In: Genant HK, Guglielmi G, Jergas M, eds.*Bone Densitometry and Osteoporosis*.Berlin, Heidelberg, Germany: Springer-Verlag; 1998:477-487.
10. Avecilla LS, **Miller PD.** Normal reference data. In: Njeh CF, FuerstHD, Glüer C-C, Genant HK, eds.*Quantitative Ultrasound: Assessment of Osteoporosis and Bone Status*. London, UK: Martin Dunitz, Ltd; 1999:221-243.
11. **Miller PD.** Osteoporosis associated with systemic illness and medications. In: Marcus R, ed. *Atlas of Clinical Endocrinology*.Philadelphia, PA: Current Medicine Group; 2000.
12. **Miller PD, Bonnicksen SL.** Clinical application of bone densitometry.In: Favus MJ, ed.*Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*. 4th ed.Philadelphia, PA: Lippincott Williams & Wilkins; 1999:152-159.
13. Sterkel BB, **Miller PD.** Bone mass measurement techniques in clinical practice.In: Avioli LV, ed. *The Osteoporotic Syndrome: Detection, Prevention, and Treatment*. 4thed.San Diego,

- CA:Academic Press; 2000:45-66.
14. **Miller PD**, Zapalowski C. Bone mineral density measurements. In: Henderson JE, Goltzman D, eds.*The Osteoporosis Primer*. Cambridge, UK: Cambridge UP; 2000:262-276.
 15. Masad T, **Miller PD**. Bone densitometry in the elderly.In: Fordham JN, ed.*Manual of Bone Densitometry Measurements: an Aid to the Interpretation of Bone Densitometry Measurements in a Clinical Setting*.London, UK: Springer-Verlag; 2000:199-219.
 16. **Miller PD**. Controversial issues in bone densitometry.In: Bilezikian JP, Raisz LG, Rodan GA, eds.*Principles of Bone Biology*.San Diego, CA: Academic Press; 2002:1587-1597.
 17. **Miller PD**. Osteoporosis.In:Rakel RE, Bope ET, eds.*Conn's Current Therapy*. Philadelphia, PA: WB Saunders Co;2002:586-598.
 18. **Miller PD**. Paget's disease.In: Rakel RE, Bope ET, eds.*Conn's Current Therapy*. Philadelphia, PA: WB Saunders Co; 2002:598-600.
 19. **Miller PD**. Osteoporosis associated with systemic illness and medications. In: Orwoll ES, ed. *Atlas of Osteoporosis*. Philadelphia, PA: Current Medicine Group; 2003:119-136.
 20. **Miller PD**.The clinical application of gender-based databases for the diagnosis of osteoporosis and fracture risk prediction.In: Legato MJ, Bilezikian JP, eds.*Principles of Gender-specific Medicine*.New York, NY: Gulf Professional Publishing (Elsevier); 2004:1033-1042.
 21. **Miller PD**.Risk factors for osteoporotic fractures.In: McDermott MT, Zapalowski C, **Miller**

- PD**, eds.*OsteoporosisHot Topics*. Philadelphia, PA: Hanley & Belfus; 2004:15-24.
22. **Miller PD**. Diagnosis of osteoporosis.In: McDermott MT, Zapalowski C, Miller PD, eds.*OsteoporosisHot Topics*. Philadelphia, PA: Hanley & Belfus; 2004:25-34.
23. McDermott MT, Zapalowski C, **Miller PD**. Treatment of osteoporosis: pharmacologic.In: McDermott MT, Zapalowski C, Miller PD, eds.*OsteoporosisHot Topics*. Philadelphia, PA: Hanley & Belfus; 2004:71-109.
24. **Miller PD**. Monitoring osteoporosis therapy.In: McDermott MT, Zapalowski C, Miller PD, eds.*OsteoporosisHot Topics*. Philadelphia, PA: Hanley & Belfus; 2004:111-121.
25. **Miller PD**. Bone mass measurement.In: Martini L, ed. *Encyclopedia of Endocrine Diseases*.New York, NY: Elsevier; 2004:378-385.
26. **Miller PD**, Shane E.Management of transplantation renal bone disease: interplay of bone mineral density and decisions regarding bisphosphonate use.In: Weir MR, ed.*Medical Management of Kidney Transplantation*.Philadelphia, PA: Lippincott Williams & Wilkins; 2004:359-375.
27. **Miller PD**, Lerma EV. Renal bone diseases.In: Kleerekoper M, Siris ES, McClung M, eds.*The Bone and Mineral Manual: A Practical Guide*. 2nd ed. Burlington, MA:Elsevier Academic Press;2005;:127-137.
28. **Miller PD**. Renal osteodystrophy. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. *Rheumatology*. 4th ed.London, UK: Elsevier;2005.

29. **Miller PD**, Huffer W. Renal osteodystrophy. In:Schrier RW, Cohen AH, eds.*Essential Atlas of Nephrology & hypertension*. 2nd ed. Philadelphia, PA: Current Medicine Group; 2006;261-276.
30. **Miller PD**, Leonard M. Clinical application of bone mass measurements. In:Favus MJ. *Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism*. 6th ed. Philadelphia, PA: LippincottWilliams &Wilkins; 2006.
31. **Miller PD**. Combination therapy for osteoporosis: what do the data tell us? In: Lane NE, Sambrook P, eds.*Osteoporosis and the Osteoporosis of Rheumatic Diseases*. Philadelphia, PA: Mosby/Elsevier; 2006:192-202.
32. Kanis JA on behalf of the World Health Organization Scientific Group (2007). Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases. Sheffield, UK: University of Sheffield; 2007. Available at: https://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. Accessed January 23, 2017. [*Dr Miller was a member of the Group.*]
33. **Miller PD**. Paget's disease of bone. In: Rakel RE, Bope ET, eds.*Conn's Current Therapy*. Philadelphia, PA: Saunders/Elsevier; 2007:718-721.
34. Camacho PM, **Miller PD**. *Osteoporosis: A Guide for Clinicians*. Philadelphia, PA: Lippincott Williams &Wilkins; 2007.
35. **Miller PD**. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In:

- Marcus R, Feldman D, Nelson D, Rosen CJ. *Osteoporosis*. 3rd ed. San Diego, CA: Elsevier Academic Press; 2007:1725-1736.
36. Faulkner KG, **Miller PD**. Clinical use of bone densitometry. In: Marcus R, Feldman D, Nelson D, Rosen CJ. *Osteoporosis*. 3rd ed. San Diego, CA: Elsevier Academic Press; 2007:1493-1515.
37. **Miller PD**. Renal bone diseases. In: Orwoll E, ed. *Atlas of Metabolic Bone Diseases*. 3rd ed. New York, NY: Springer; 2008:135-146.
38. **Miller PD**. Osteoporosis in men with impaired renal function. In: Orwoll ES, Bilezikian JP, Vanderschueren D. *Osteoporosis in Men*. 2nd ed. San Diego, CA: Academic Press/Elsevier; 2010:453-464.
39. **Miller PD**. Renal osteodystrophy. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. *Rheumatology*. 5th ed. Philadelphia, PA: Mosby/Elsevier; 2010:2013-2019.
40. **Miller PD**. Rickets, osteomalacia, and renal osteodystrophy. In: Iannotti JP, Parker RD, eds. *The Netter Collection of Medical Illustrations*, vol 6. Philadelphia, PA: Saunders/Elsevier; 2012:3(13)-3(16).
41. **Miller PD**. Diseases of mineral metabolism and bone: emerging therapeutics for postmenopausal osteoporosis. In: Bronner F, Farach-Carson MC, Roach HI, eds. *Bone—Metabolic Functions and Modulators*. London, UK: Springer-Verlag; 2012:147-162.
42. Bonnick SL, **Miller PD**. Clinical use of bone densitometry. In: Marcus R, Feldman D,

- Dempster DW, Luckey M, Cauley JA, eds. *Osteoporosis*. 4th ed. Waltham, MA: Academic Press/Elsevier; 2013:1551-1568.
43. Diab DL, Watts NB, **Miller PD**. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Dempster DW, Luckey M, Cauley JA, eds. *Osteoporosis*. 4th ed. Academic Press/Elsevier: Waltham, MA; 2013:1859-1872.
44. **Miller PD**, Watts NB. Bisphosphonates. In: Stovall DW, ed. *Osteoporosis: Diagnosis and Management*. Oxford, UK: John Wiley & Sons; 2013:123-143.
45. **Miller PD**, Jamal S, Sprague SM. Clinical skeletal syndromes associated with parathyroid disorders in chronic kidney disease. In: Bilezikian JP, Marcus R, Levine MA, Marcocci C, Silverberg SJ, Potts JT Jr. *The Parathyroids: Basic and Clinical Concepts*. 3rd ed. Waltham, MA: Academic Press/Elsevier; 2014:653-669.
46. **Miller PD**. Renal osteodystrophy. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. *Rheumatology*. 6th ed. Philadelphia, PA: Elsevier Mosby; 2014:1692-1697.
47. **Miller PD**. Osteoporosis in patients with chronic kidney disease: diagnosis, evaluation, and management. UpToDate. Available at: <http://www.uptodate.com/contents/osteoporosis-in-patients-with-chronic-kidney-disease-diagnosis-evaluation-and-management>. Last updated September 28, 2016.
48. **Miller, P. D.**, Bilezikian, J. P., Lewiecki, E. M., Watts, N. B. and Carey, J. J. (2018), Re: A History of Pivotal Advances in Clinical Research Into Bone and Mineral Diseases. *J Bone Miner Res*, 33: 1900-1901. doi:10.1002/jbmr.3566